UGA receives $6.7 M grant that will add knowledge in fights against cancer, Parkinson's disease

September 05, 2003

The National Center for Research Resources (NCRR), a component of the National Institutes of Health, has awarded a five-year grant of $6.7 million to a team headed by scientists at the University of Georgia for research that could eventually help in the treatment of certain kinds of cancer and Parkinson's Disease.

The grant is cosponsored by the National Cancer Institute and thereby counts toward the total award dollars needed to apply for an NCI Comprehensive Cancer Center Planning Award. This could be an important step in progress for the Georgia Cancer Coalition, in which UGA is collaborating with the Medical College of Georgia in Augusta to form the Georgia Cancer Research Center.

"This grant demonstrates yet again the quality of our faculty involved in research at the University of Georgia," said President Michael F. Adams. "The potential to alleviate human suffering through this work makes it tremendously important."

The large-scale cooperative project will include researchers from UGA, Georgia Tech, the Winship Cancer Institute of Emory University, Yale University and Bresagen, Inc., as well as scientists from Japan.

"We are delighted that our work is increasingly drawing this kind of support," said Michael Pierce, principal investigator for the grant and faculty member at the Complex Carbohydrate Research Center and the Department of Biochemistry and Molecular Biology. "It demonstrates the high quality of our faculty and staff at the CCRC and at UGA, as well as those at Georgia Tech."

The NCRR supports primary research to create and develop critical resources, models and technologies. NCRR funding also provides biomedical researchers with access to diverse instrumentation, technologies, basic and clinical research facilities, animal models, genetic stocks, biomaterials and more. These resources enable scientific advances in biomedicine that lead to the development of lifesaving drugs, devices and therapies.

The research funded by the grant will focus on technologies to map the "glycome" of stem cell lines established by Bresagen, a private research company with offices and laboratories in Athens. "Glycome" describes all the complex carbohydrates attached to proteins and lipids that are made by a cell, as well as the enzymes responsible for their metabolism. It also describes the carbohydrate binding proteins that function by recognizing these complex carbohydrates.

"This proposal was one of only seven funded nationally in this first grant competition, so naturally, we are pleased," said Pierce.

This technology will allow the glycomic analysis of small numbers of cells and the means to isolate or kill these particular cells. The expected outcome will be directly applicable to the isolation of certain types of nerve cells for treatment of such diseases as Parkinson's, as well as development of new ways to diagnose and treat cancer.

Others in the research project include Kelley Moremen, Ron Orlando, Parastoo Asadi and Will York of the CCRC; Armit Sheth, John Miller and Krzysztof Kochut of UGA's computer science department and its Large Scale Distributed Information Systems Laboratory; Ian Lyons of Bresagen, Inc. (and an adjunct professor of biochemistry and molecular biology at UGA); and Alfred Merrill of Georgia Tech.

The Georgia Cancer Coalition (GCC) is a statewide public-private network of people and organizations - doctors, hospitals, government agencies, public health services, survivor and community health groups, universities, industries, nonprofits and interested individuals - working together to save lives and reduce human suffering from cancer.

Russ Toal, president of the Georgia Cancer Coalition, noted that "this grant award underscores Georgia's and UGA's determination to fight cancer with the best weapons in our arsenal: university leadership, quality faculty, world-class research, multi-institutional collaborations, public-private partnerships and commitment to being a leader in the war against this killer. We congratulate Dr. Pierce and his colleagues for all their good work, and we will do all we can to support their efforts in the years ahead."
-end-


University of Georgia

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.